Decreasing rate of multiple treatment modifications among individuals who initiated antiretroviral therapy in 1997-2009 in the Danish HIV Cohort Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Decreasing rate of multiple treatment modifications among individuals who initiated antiretroviral therapy in 1997-2009 in the Danish HIV Cohort Study. / Helleberg, Marie; Kronborg, Gitte; Larsen, Carsten Schade; Pedersen, Gitte; Pedersen, Court; Nielsen, Lars Nørregård; Laursen, Alex Lund; Obel, Niels; Gerstoft, Jan.
I: Antiviral Therapy, 2013.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Decreasing rate of multiple treatment modifications among individuals who initiated antiretroviral therapy in 1997-2009 in the Danish HIV Cohort Study
AU - Helleberg, Marie
AU - Kronborg, Gitte
AU - Larsen, Carsten Schade
AU - Pedersen, Gitte
AU - Pedersen, Court
AU - Nielsen, Lars Nørregård
AU - Laursen, Alex Lund
AU - Obel, Niels
AU - Gerstoft, Jan
PY - 2013
Y1 - 2013
N2 - BACKGROUND: We hypothesized that rates and reasons for treatment modifications have changed since the implementation of combination antiretroviral therapy (cART) due to improvements in therapy. METHODS: From a nationwide population-based cohort study we identified all HIV-1 infected adults who initiated cART in Denmark 1997-2009 and were followed (3)1 year. Incidence rate ratios (IRR) and reasons for treatment modifications were estimated and compared between patients, who initiated treatment in 1997-1999, 2000-2004 and 2005-2009. Rates of discontinuation of individual antiretroviral drugs (ARVs) were evaluated. RESULTS: 3,107 patients were followed median 7.3 years (IQR 3.8-10.8). Rates of first treatment modification ≤1 year after cART initiation did not change (IRR 0.88 (95% CI 0.78-1.01) and 1.03 (95% CI 0.90-1.18) in 2000-2004 and 2005-2009 compared to 1997-1999). Rates of multiple modifications decreased markedly (2000-2004: IRR 0.60 (95% CI 0.53-0.67) and 2005-2009 0.38 (95% CI 0.32-0.46)). Rates of treatment modifications due to virological failure, toxicity and other/unknown reasons decreased (IRR 0.25 (95% CI 0.14-0.45), 0.69 (95% CI 0.56-0.83) and 0.45 (95% CI 0.36-0.57) in 2005-2009 compared to 1997-1999), while the rate of modifications with the aim of simplification increased (IRR 1.85 (95% CI 1.52-2.25)). CONCLUSIONS: Rates of first treatment modification ≤1 year after cART initiation have not changed since the early cART era, while the risk of multiple modifications has decreased markedly. Modifications due to virological failure and toxicity have decreased substantially, while rates of switch to simpler and less toxic regimens have increased.
AB - BACKGROUND: We hypothesized that rates and reasons for treatment modifications have changed since the implementation of combination antiretroviral therapy (cART) due to improvements in therapy. METHODS: From a nationwide population-based cohort study we identified all HIV-1 infected adults who initiated cART in Denmark 1997-2009 and were followed (3)1 year. Incidence rate ratios (IRR) and reasons for treatment modifications were estimated and compared between patients, who initiated treatment in 1997-1999, 2000-2004 and 2005-2009. Rates of discontinuation of individual antiretroviral drugs (ARVs) were evaluated. RESULTS: 3,107 patients were followed median 7.3 years (IQR 3.8-10.8). Rates of first treatment modification ≤1 year after cART initiation did not change (IRR 0.88 (95% CI 0.78-1.01) and 1.03 (95% CI 0.90-1.18) in 2000-2004 and 2005-2009 compared to 1997-1999). Rates of multiple modifications decreased markedly (2000-2004: IRR 0.60 (95% CI 0.53-0.67) and 2005-2009 0.38 (95% CI 0.32-0.46)). Rates of treatment modifications due to virological failure, toxicity and other/unknown reasons decreased (IRR 0.25 (95% CI 0.14-0.45), 0.69 (95% CI 0.56-0.83) and 0.45 (95% CI 0.36-0.57) in 2005-2009 compared to 1997-1999), while the rate of modifications with the aim of simplification increased (IRR 1.85 (95% CI 1.52-2.25)). CONCLUSIONS: Rates of first treatment modification ≤1 year after cART initiation have not changed since the early cART era, while the risk of multiple modifications has decreased markedly. Modifications due to virological failure and toxicity have decreased substantially, while rates of switch to simpler and less toxic regimens have increased.
U2 - 10.3851/IMP436
DO - 10.3851/IMP436
M3 - Journal article
C2 - 23072939
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
ER -
ID: 48451816